The efficiency of ibrutinib in these cancers has already been proposed in previous publications [19, 29, 30], and we indeed found ibrutinib to be the most potent BTK inhibitor of ERBB signalling in breast cancer cell lines, once again confirming its anticancer effects. The gene discussed is BTK; the disease is breast carcinoma.